View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 30, 2020updated 12 Jul 2022 11:44am

Medable and Datavant to simplify data source integration for trials

Medable, a US-based software provider for decentralised clinical trials, and Datavant, a firm that aids healthcare organisations connect their data, have partnered to help clinical trial teams easily integrate multiple data sources.

Medable, a US-based software provider for decentralised clinical trials, and Datavant, a firm that aids healthcare organisations connect their data, have partnered to help clinical trial teams easily integrate multiple data sources.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

With the intergration of several data sources, it becomes possible to speed up decentralised trial design, recruitment, and data management.

Medable will integrate Datavant’s technology into its decentralised trials platform, enabling trial teams to bring together real-world health records, claims, diagnostic and other data sources with clinical trial data.

This integration will remove several manual and time-taking steps, which in turn slow down clinical trials.

Furthermore, it boosts patient access and helps trial teams to optimise evidence generation both during and after studies.

Medable CEO and co-founder Michelle Longmire said: “Making it easier to integrate multiple data sources is an important step in our mission to reduce clinical trial timelines by 50%.

“Datavant provides us with a broad array of built-in connections to real-world data sources, which can now be combined to yield a more holistic view of patient health than clinical trial data alone.”

Datavant’s technology enables linking de-identified data across a patient’s complete journey.

On linking real-world data sources with other sources of study data, the team working on the clinical trial will be able to produce and submit real-world evidence for regulatory analysis.

Datavant CEO Travis May said: “Accelerating the pace of clinical development will help patients get access to life-saving therapies more quickly.

“We’re excited to help power Medable’s work in accelerating clinical trials by making it easier to connect to the ecosystem of real-world data.”

Earlier this year, Medable began working with Datavant as part of a multi-company research framework to speed up the development of diagnostics and treatments for Covid-19.

The ACCESS initiative, which stands for American Covid-19 Collaborative Enabling Seamless Science, offers a mobile application and safe infrastructure to link health researchers and clinical trial teams with individuals in the US.

Last month, US-based life sciences firm LabCorp has announced that Covance, its drug development business, is bolstering its technology ecosystem to speed up the adoption of decentralised clinical trials.

Through an alliance with software provider for digital clinical trials Medable, Covance is expanding its decentralised clinical trials technology ecosystem.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena